Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4319331 | Brain Research Bulletin | 2010 | 7 Pages |
Abstract
Nociceptin/orphanin FQ (N/OFQ) is an endogenous neuropeptide, which is widely distributed in central and peripheral nervous system. Some N/OFQ sequence unrelated hexapeptides can effectively bind to the N/OFQ peptide (NOP) receptor and they were used as template for structure-activity studies that lead to discovery of the new NOP selective ligands. In the present study, the pharmacological profile of the novel hexapeptide Ac-RYYRIR-ol was investigated using various in vitro assays including receptor binding and G-protein activation in rat brain membranes, mouse and rat vas deferens, guinea pig ileum, mouse colon and Ca2+ mobilization assay in chinese hamster ovary (CHO) cells co-expressing the human recombinant NOP receptor and the C-terminally modified Gαqi5 protein. In rat brain membranes Ac-RYYRIR-ol displaced both [3H]nociceptin/OFQ and [3H]Ac-RYYRIK-ol with high affinity (pKi 9.35 and 8.81, respectively) and stimulated [35S]GTPγS binding showing however lower maximal effects than N/OFQ (α = 0.28). The stimulatory effect of Ac-RYYRIR-ol was antagonized by the selective NOP receptor antagonist UFP-101. In the electrically stimulated mouse vas deferens Ac-RYYRIR-ol displayed negligible agonist activity while antagonizing in a competitive manner (pA2 7.99) the inhibitory effects of N/OFQ. Similar results were obtained in the rat vas deferens. In the mouse colon Ac-RYYRIR-ol produced concentration dependent contractile effects with similar potency and maximal effects as N/OFQ. Finally, in the Ca2+ mobilization assay performed with CHO-hNOP-Gαqi5 cells Ac-RYYRIR-ol displayed lower potency and maximal effects (α = 0.87) compared with N/OFQ. In conclusion, the novel NOP receptor selective hexapeptide Ac-RYYRIR-ol has been shown to have fine selectivity, high potency, furthermore agonist and antagonist effects toward the NOP receptors were measured in various assays; this is likely due to its partial agonist pharmacological activity.
Keywords
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Engin Bojnik, Fruzsina Babos, Carmela Fischetti, Anna Magyar, Valeria Camarda, Anna Borsodi, Sándor Bajusz, Girolamo Calo', Sándor Benyhe,